# Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

> **NCT05283915** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 10 (actual)

## Conditions studied

- Hepatic Function Abnormal

## Interventions

- **DRUG:** tolebrutinib

## Key facts

- **NCT ID:** NCT05283915
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283915, "Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05283915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*